Cheaper drugs produce same benefits for rheumatoid arthritis, study finds

June 13, 2013 by Will Ackerman, University of Nebraska-Lincoln

James O'Dell, M.D., chief of the Veterans Administration Nebraska-Western Iowa Health Care System's Omaha medical center and the UNMC divisions of rheumatology and immunology, is the primary author of a study that has been published in the New England Journal of Medicine.

In the large U.S. Department of Veterans Affairs cooperative blinded study that compared the effectiveness of drug therapies for , Dr. O'Dell and his fellow researchers found that the use of less expensive combination disease-modifying anti-rheumatic drugs (DMARDs) produced the same clinical benefits as much more expensive .

In a 48-week study, researchers compared the strategy of first starting oral, "triple therapy" DMARDS, methotrexate, sulfasalazine and , to that of first starting one DMARD (methotrexate) plus etanercept. Etanercept is part of a class of injectable drugs called factors (TNF) antagonist or anti-TNF therapy, also known as biologics.

"Before the study, there was a general belief that biologics have significantly more potency, but this study has proven that not to be the case in this patient population," said Dr. O'Dell. "The study shows when is used before biologics, there should be a significant cost savings not only to patients, but to the ."

The study included 353 patients at 16 VA medical centers, 12 rheumatoid arthritis investigational network sites and eight Canadian medical centers, which included the Omaha VA Medical Center and The Nebraska Medical Center. The double-blind study is one where neither the patients nor their physicians knew which regimen they were receiving.

Patients were divided into two groups: one took the triple therapy combination first, while the other took methotrexate and etanercept first for 24 weeks. Patients who didn't respond to either therapy were switched to the other therapy at 24 weeks for the last 24 weeks of the study. Patients in both groups who switched to the other therapy improved, but the response after switching was not significantly different between the two study groups.

The final study outcome was that both strategies resulted in significant and similar improvement over 48 weeks. In addition there were no significant differences in secondary outcomes including radiographic progression, pain, health-related quality of life or for the most part adverse events associated with any of the medications.

Results, now on the New England Journal of Medicine's web page, will also appear in the July 25 print edition.

Explore further: Rheumatoid arthritis patients not taking their medications as prescribed

More information: www.nejm.org/doi/full/10.1056/ … ?query=featured_home

Related Stories

Rheumatoid arthritis patients not taking their medications as prescribed

May 30, 2013
A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis (RA) patients had an overall adherence rate to prescribed oral medications at 80% or ...

Data suggest smoking doesn't impact RA treatment response

December 21, 2012
(HealthDay)—For patients with early rheumatoid arthritis (RA), smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according to a study ...

Long-term apremilast demonstrates continued efficacy in patients with psoriatic arthritis

June 12, 2013
New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses ...

ACR updates guidelines for use of DMARDs and biologic drugs in treating rheumatoid arthritis

April 2, 2012
The American College of Rheumatology (ACR) has released the 2012 recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA). The guidelines ...

Use of biologic therapies for inflammatory diseases does not appear to increase risk of shingles

April 19, 2013
Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment ...

Significant improvements in psoriatic arthritis with ustekinumab

June 12, 2013
New PSUMMIT 2* data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).

Recommended for you

Joint resolution: A link between Huntington's disease and rheumatoid arthritis

May 15, 2018
Using new analytic tools, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have decoded the epigenetic landscape for rheumatoid arthritis (RA), a common ...

Get off the golf cart if you have knee osteoarthritis

April 28, 2018
From presidents to retirees, more than 17 million people over the age of 50 golf regularly. Knee osteoarthritis, which causes swelling, pain and difficulty moving the joint, is one of the leading causes of disability in this ...

How environmental pollutants and genetics work together in rheumatoid arthritis

April 19, 2018
It has been known for more than three decades that individuals with a particular version of a gene—human leukocyte antigen (HLA)—have an increased risk for rheumatoid arthritis.

The bugs in your gut could make you weak in the knees

April 19, 2018
Bacteria in the gut, known as the gut microbiome, could be the culprit behind arthritis and joint pain that plagues people who are obese, according to a new study published today in JCI Insight.

Researchers identify peptide produced during cartilage deterioration as a potential source of osteoarthritis pain

April 11, 2018
Osteoarthritis is one of the most common causes of chronic pain in the world. More than 30 million people in the United States alone suffer from osteoarthritis, or OA, which can affect any moveable joint of the body, including ...

Flare-responsive hydrogel developed to treat arthritis

April 3, 2018
Arthritis flares - the unpredictable and often sudden worsening of arthritis symptoms—can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.